Are there pulmonary sequelae in patients recovering from COVID-19?

Rogliani, Paola; Calzetta, Luigino; Coppola, Angelo; Puxeddu, Ermanno; Sergiacomi, Gianluigi; D'Amato, Dejanira; Orlacchio, Antonio

Rogliani, Paola; Calzetta, Luigino; Coppola, Angelo; Puxeddu, Ermanno; Sergiacomi, Gianluigi; D'Amato, Dejanira; Orlacchio, Antonio.

Rogliani P; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy. paola.rogliani@uniroma2.it.
Calzetta L; Division of Respiratory Medicine, University Hospital "Policlinico Tor Vergata", Rome, Italy. paola.rogliani@uniroma2.it.
Coppola A; Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Puxeddu E; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Sergiacomi G; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
D'Amato D; Division of Respiratory Medicine, University Hospital "Policlinico Tor Vergata", Rome, Italy.
Orlacchio A; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome Tor Vergata, Rome, Italy.

Respir Res ; 21(1): 286, 2020 Oct 30.

Article in English | MEDLINE | ID: covidwho-895006

ABSTRACT

ABSTRACT

It has been recently hypothesized that infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to fibrotic sequelae in patients recovering from coronavirus disease 2019 (COVID-19). In this observational study, hospitalized patients with COVID-19 had a HRCT of the chest performed to detect the extension of fibrotic abnormalities via Hounsfield Units (HU). At follow-up, the lung density significantly improved in both lungs and in each lobe of all patients, being in the normal range (- 950 to - 700 HU). This study provides preliminary evidence that hospitalized patients with mild-to-moderate forms of COVID-19 are not at risk of developing pulmonary fibrosis.

Subject(s)

Coronavirus Infections/complications; Disease Progression; Pneumonia, Viral/complications; Pulmonary Fibrosis/diagnostic imaging; Severe Acute Respiratory Syndrome/complications; Severe Acute Respiratory Syndrome/therapy; Aged; COVID-19; Cohort Studies; Combined Modality Therapy; Confidence Intervals; Coronavirus Infections/diagnosis; Female; Follow-Up Studies; Hospitalization/statistics & numerical data; Hospitals, University; Humans; Italy; Male; Middle Aged; Pandemics; Pneumonia, Viral/diagnosis; Prospective Studies; Pulmonary Fibrosis/epidemiology; Pulmonary Fibrosis/pathology; Radiography, Thoracic/methods; Risk Assessment; Severe Acute Respiratory Syndrome/diagnosis

Keywords

COVID-19; HRCT; Pulmonary fibrosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Pulmonary Fibrosis / Coronavirus Infections / Disease Progression / Severe Acute Respiratory Syndrome Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Respir Res Year: 2020 Document Type: Article Affiliation country: S12931-020-01550-6

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google